Founder-led sales for agencies: how to productise the offering for healthcare and life sciences in Latin America
The service design, pricing, and delivery model for running founder-led sales as a productised offering inside a services firm. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install founder-led sales has to be shaped to that reality from day one.
Founder-led sales is one of the highest-margin offerings an agency can add in 2026. It is the founder personally running discovery, closing, and post-sale for the first 100 customers, and clients will pay a premium for the discipline they cannot install themselves.
Productise around outcome, not activity. Sell founder hours per week in customer conversations moving to a defined level in a defined window, not a monthly retainer of vague ops.
Delivery pod: one strategist, one operator, one editor. Fewer people than that risks quality; more than that dilutes margin.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Founder-led sales is only useful here when it is pointed at both constraints at once.
Onboarding takes two weeks: diagnosis, list build, trigger definition, kill criteria. Do not ship anything live before the diagnosis is signed off.
Pricing: outcome-linked base plus a monthly ops fee. The base rewards results; the ops fee funds the delivery pod.
Client failure mode: hiring VP of Sales at $500k ARR to escape sales. Write it into the engagement letter as a shared risk, not something you absorb quietly.
The agencies making the most from founder-led sales are the ones with the tightest playbook. Documented, versioned, and improved every quarter.
Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing founder-led sales deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · LATAM — answered
- Does founder-led sales work for healthcare and life sciences in Latin America?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
- How should agencies price founder-led sales?
- Outcome-linked base plus a monthly ops fee. Avoid pure retainer.
- What is the minimum delivery pod?
- Strategist, operator, editor. Three roles, not necessarily three headcount at small scale.
- How long is agency onboarding for founder-led sales?
- Two weeks: diagnosis, list, trigger, kill criteria.
- What client behaviour breaks the engagement?
- Hiring VP of Sales at $500k ARR to escape sales — bake shared risk into the contract.
- What is the LATAM-specific pitfall when running founder-led sales for healthcare?
- Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · latam